Stockscreener 앱 받기
1.36
1.45%
-0.02
시간 외 거래:
1.36
전일 마감가:
$1.38
열려 있는:
$1.36
하루 거래량:
63,445
Relative Volume:
0.70
시가총액:
$19.82M
수익:
$10.96M
순이익/손실:
$-7.02M
주가수익비율:
-2.125
EPS:
-0.64
순현금흐름:
$-3.72M
1주 성능:
-3.55%
1개월 성능:
-57.23%
6개월 성능:
-62.22%
1년 성능:
-72.64%
1일 변동 폭
$1.32
$1.40
1주일 범위
$1.32
$1.54
52주 변동 폭
$1.32
$5.48
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
CLGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
1.36 | 19.82M | 10.96M | -7.02M | -3.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-17 | 개시 | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd 주식(CLGN)의 최신 뉴스
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative - Barchart.com
CollPlant shares rise on expanded partnership with STEMCELL Technologies - MSN
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES - marketscreener.com
CollPlant (CLGN) Expands Partnership with STEMCELL Technologies - GuruFocus
CollPlant Biotechnologies (CLGN) Shares Surge on Expanded STEMCE - GuruFocus
CollPlant's Plant-Based Collagen Advances to Clinical Applications in Major STEMCELL Technologies Deal - Stock Titan
CollPlant secures European patent for collagen products By Investing.com - Investing.com South Africa
CollPlant Biotechnologies Announces European Patent Acceptance Secured for Its Collaboration Multiple as Soft Tissue Fillers and Implants - marketscreener.com
CollPlant secures European patent for collagen products - Investing.com Australia
CollPlant (CLGN) Secures European Patent for Injectable Fillers and Implants | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS - MENAFN.com
CollPlant Biotechnologies Announces $3.6 Million Securities Offering - TipRanks
SEC Form 424B5 filed by CollPlant Biotechnologies Ltd - Quantisnow
SEC Form 6-K filed by CollPlant Biotechnologies Ltd - Quantisnow
CollPlant Biotechnologies shares slide after announces capital raise of $3.6M through registered direct offering - MSN
CollPlant Biotechnologies First Quarter 2025 Earnings: Misses Expectations - simplywall.st
CollPlant announces $3.6 million stock offering By Investing.com - Investing.com South Africa
CollPlant (CLGN) Announces $3.6M Direct Offering and Private Pla - GuruFocus
Dow Edges Higher; Dell Shares Fall After Q1 Results - Benzinga
CollPlant Biotechnologies Launches Share Offering; Stock Drops - marketscreener.com
CollPlant Biotechnologies (CLGN) Rating and Price Target Analysis | CLGN Stock News - GuruFocus
CollPlant (CLGN) Announces New Share and Warrant Sale Agreement - GuruFocus
CollPlant (CLGN) Announces New Share and Warrant Sale Agreement | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRE - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES - Quantisnow
CollPlant announces $3.6 million stock offering - Investing.com Australia
CollPlant Raises $3.6M to Advance AbbVie Partnership and Breakthrough Regenerative Medicine Programs - Stock Titan
CollPlant Biotechnologies (NASDAQ:CLGN) Price Target Lowered to $12.00 at D. Boral Capital - Defense World
CollPlant Biotechnologies Reports Strong Q1 2025 Results - TipRanks
Collplant Biotechnologies Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
CollPlant Biotechnologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
CollPlant Biotechnologies (CLGN) Analyst Ratings Update | CLGN S - GuruFocus
CollPlant Biotechnologies (CLGN) Analyst Ratings Update | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL R - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - PR Newswire
CollPlant Biotechnologies (CLGN) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Earnings Preview: CollPlant Biotechnologies - Nasdaq
Global Tissue Engineering Market Insights & Industry Outlook | - openPR.com
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven? - simplywall.st
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINAN - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS - Financial Times
Renaissance Technologies LLC Acquires New Stake in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation - Yahoo Finance
CLGNCollplant Biotechnologies Ltd Latest Stock News & Market Updates - Stock Titan
Collplant stock hits 52-week low at $2.14 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $2.14 amid market challenges By Investing.com - Investing.com South Africa
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevan - GuruFocus
FDA Animal Testing Phase-Out: How CollPlant's BioInk Tech Could Revolutionize Drug Safety Studies - Stock Titan
Collplant Biotechnologies Ltd (CLGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.23%
자본화:
|
볼륨(24시간):